HCV Treatment
Positive hepatitis C, hepatitis B treatment results released
Published in Hepatitis Weekly, May 5th, 2003
NM283, a ribonucleoside analog being developed as an oral, once-daily treatment, appeared to be well tolerated and after 1 week of treatment reduced mean viral load by over 90% (1 log10) in a primate model of human chronic HCV infection.
Idenix also presented 24-week data from an ongoing phase IIb trial of telbivudine (LdT) for the treatment of hepatitis B virus (HBV) infection, further demonstrating its promising safety and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-05-05)
More Articles from Hepatitis Weekly
- DNA Vaccine
Transdermal gene delivery eradicates tumors expressing hepatitis C proteins - Radiology
Magnetic resonance spectroscopy could replace the use of HCV-related biopsy - Adoptive Immunotherapy
Roadblocks to tumor vaccines could be overcome with interleukin-2 - Hepatitis C Therapy
The choice to continue therapy for chronic hepatitis C can be made in 12 weeks - Virology
Core-envelope 1-based assays can quickly distinguish hepatitis C virus subtypes - Virology
The Hungarian population is host to several different TT virus genotypes - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
